COMMUNIQUÉS West-GlobeNewswire

AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

05/11/2018 - 14:00

GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO [...]

Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

05/11/2018 - 14:00

HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]

Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)

05/11/2018 - 14:00

SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on the company’s small molecule Wnt pathway inhibitor, SM04690, in four poster presentations [...]

Rexahn Reports Third Quarter 2018 Financial Results

05/11/2018 - 14:00

ROCKVILLE, Md., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, [...]

Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

05/11/2018 - 14:00

Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological [...]

Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update

05/11/2018 - 14:00

Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa PITTSBURGH, Nov. 05, [...]

Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells

05/11/2018 - 14:00

VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed [...]

Transactions under Novozymes’ stock buyback program

05/11/2018 - 13:40

Please read the full announcement in the attached PDF Attachment 2018_62_Stock_Buybackprogram_EN

Elite Pharmaceuticals Launches Generic Methadone Tablets

05/11/2018 - 13:30

NORTHVALE, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, [...]

Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates

05/11/2018 - 13:30

Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the [...]

Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018

05/11/2018 - 13:30

SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, [...]

FDA Approves Novel Single-Vial Formulation of EGRIFTA®

05/11/2018 - 13:30

MONTREAL, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Food and Drug Administration in the United States has approved the new single-vial [...]

La FDA approuve la nouvelle formulation d’EGRIFTA(MD) en fiole unique

05/11/2018 - 13:30

MONTRÉAL, 05 nov. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que la Food and Drug Administration aux États-Unis a approuvé la nouvelle formulation en fiole [...]

Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

05/11/2018 - 13:30

– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc [...]

Radient Technologies Inc. Appoints Mr. Christian Aigner as Managing Director, Germany, and Announces European and Canadian Plant Expansions

05/11/2018 - 13:30

EDMONTON, Alberta, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce it has appointed Mr. Christian Aigner to the position of Managing [...]

Release date of nine-month interim report (Q3) 2018 and audio cast

05/11/2018 - 13:29

On Friday, 9 November 2018, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its interim report for the six months ended 30 September 2018. ALK will host a meeting for analysts and institutional investors that day [...]

Myriad Receives the Prestigious 2018 Utah Top Workplaces Award

05/11/2018 - 13:05

SALT LAKE CITY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced its recognition as a 2018 recipient of the Utah Top [...]

Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET

05/11/2018 - 13:00

CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal [...]

Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018

05/11/2018 - 13:00

BRIDGEWATER, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release [...]